{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:13Z","timestamp":1792800913121,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Shanghai Clinical Research Center for Infectious Disease","award":["19MC1910800"],"award-info":[{"award-number":["19MC1910800"]}],"id":[{"id":"https:\/\/ror.org\/057tkkm33","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Shanghai Scientific and Technological Innovation Project","award":["22Y11900700"],"award-info":[{"award-number":["22Y11900700"]}]},{"name":"Three Year Action Plan for the Construction of Shanghai Public Health System","award":["GWVI-11.2-XD02"],"award-info":[{"award-number":["GWVI-11.2-XD02"]}]},{"name":"Shanghai Nature Science Foundation","award":["21ZR1453400"],"award-info":[{"award-number":["21ZR1453400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the effectiveness and safety of linezolid-containing regimens for treatment of\n                      <jats:italic>M. abscessus<\/jats:italic>\n                      pulmonary disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The records of 336 patients with\n                      <jats:italic>M. abscessus<\/jats:italic>\n                      pulmonary disease who were admitted to Shanghai Pulmonary Hospital from January 2018 to December 2020 were retrospectively analyzed. A total of 164 patients received a linezolid-containing regimen and 172 controls did not. The effectiveness, safety, antibiotic susceptibility profiles, outcomes, culture conversion, cavity closure, and adverse reactions were compared in these two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The two groups had similar treatment success (56.1% vs. 48.8%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05), but treatment duration was shorter in the linezolid group (16.0 months [inter-quartile ranges, IQR: 15.0\u201317.0] vs. 18.0 months [IQR: 16.0\u201318.0];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). The rates of sputum culture conversion were similar (53.7% vs. 46.5%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05), but time to conversion was shorter in the linezolid group (3.5 months [IQR: 2.5\u20134.4] vs. 5.5 months [IQR: 4.0\u20136.8];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). The linezolid group had a higher rate of cavity closure (55.2% vs. 28.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) and a shorter time to cavity closure (3.5 months [IQR: 2.5\u20134.4] vs. 5.5 months [IQR: 4.0\u20136.8];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Anemia and peripheral neuropathy were more common in the linezolid group (17.7% vs. 1.7%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01; 12.8% vs. 0.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The linezolid and control groups had similar treatment success rates. The linezolid group had a shorter treatment duration, shorter time to sputum culture conversion, and higher rate and shorter time to lung cavity closure. More patients receiving linezolid developed anemia and peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12941-023-00655-2","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:02:02Z","timestamp":1701860522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Li-ping","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-na","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-rong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"Suppl2","key":"655_CR1","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-21097","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary Disease (NTM-PD). Thorax. 2017;72(Suppl2):ii1\u2013ii64. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-21097.","journal-title":"Thorax"},{"key":"655_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","volume":"11","author":"CN Ratnatunga","year":"2020","unstructured":"Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of Non-tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303. https:\/\/doi.org\/10.3389\/fimmu.2020.00303.","journal-title":"Front Immunol"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"919474","DOI":"10.1155\/2014\/919474","volume":"2014","author":"M Mirsaeidi","year":"2014","unstructured":"Mirsaeidi M, Farshidpour M, Allen MB, Ebrahimi G, Falkinham JO. Highlight on advances in Nontuberculous Mycobacterial Disease in North America. Biomed Res Int. 2014;2014:919474. https:\/\/doi.org\/10.1155\/2014\/919474.","journal-title":"Biomed Res Int"},{"issue":"1","key":"655_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s12879-019-4412-6","volume":"19","author":"C Hu","year":"2019","unstructured":"Hu C, Huang L, Cai M, Wang W, Shi X, Chen W, et al. Characterization of non-tuberculous mycobacterial pulmonary Disease in Nanjing district of China. BMC Infect Dis. 2019;19(1):764. https:\/\/doi.org\/10.1186\/s12879-019-4412-6.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"655_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jinf.2021.05.019","volume":"83","author":"Y Tan","year":"2021","unstructured":"Tan Y, Deng Y, Yan X, Liu F, Tan Y, Wang Q, et al. Nontuberculous mycobacterial pulmonary Disease and associated risk factors in China: a prospective surveillance study. J Infect. 2021;83(1):46\u201353. https:\/\/doi.org\/10.1016\/j.jinf.2021.05.019.","journal-title":"J Infect"},{"key":"655_CR6","doi-asserted-by":"publisher","unstructured":"Cheng LP, Chen SH, Lou H, Gui XW, Shen XN, Cao J, et al. Factors Associated with Treatment Outcome in patients with Nontuberculous Mycobacterial Pulmonary Disease: a large Population-based Retrospective Cohort Study in Shanghai. Trop Med Infect Dis. 2022;7(2). https:\/\/doi.org\/10.3390\/tropicalmed7020027.","DOI":"10.3390\/tropicalmed7020027"},{"issue":"1","key":"655_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","volume":"161","author":"DE Griffith","year":"2022","unstructured":"Griffith DE, Daley CL. Treatment of Mycobacterium abscessus Pulmonary Disease. Chest. 2022;161(1):64\u201375. https:\/\/doi.org\/10.1016\/j.chest.2021.07.035.","journal-title":"Chest"},{"issue":"3","key":"655_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ijantimicag.2016.10.024","volume":"49","author":"G Li","year":"2017","unstructured":"Li G, Pang H, Guo Q, Huang M, Tan Y, Li C, et al. Antimicrobial susceptibility and MIC distribution of 41 Drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. Int J Antimicrob Agents. 2017;49(3):364\u201374. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.10.024.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"655_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/cid\/ciz071","volume":"69","author":"DE Griffith","year":"2019","unstructured":"Griffith DE. Mycobacterium abscessus and Antibiotic Resistance: same as it ever was. Clin Infect Dis. 2019;69(10):1687\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz071.","journal-title":"Clin Infect Dis"},{"key":"655_CR10","doi-asserted-by":"publisher","unstructured":"Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, et al. Mycobacterium abscessus pulmonary Disease: individual patient data meta-analysis. Eur Respir J. 2019;54(1). https:\/\/doi.org\/10.1183\/13993003.01991-2018.","DOI":"10.1183\/13993003.01991-2018"},{"key":"655_CR11","doi-asserted-by":"publisher","unstructured":"Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and Disease recurrence. Antimicrob Agents Chemother. 2017;61(11). https:\/\/doi.org\/10.1128\/AAC.01206-17.","DOI":"10.1128\/AAC.01206-17"},{"key":"655_CR12","doi-asserted-by":"publisher","unstructured":"Falzon D, Sch\u00fcnemann HJ, Harausz E, Gonz\u00e1lez-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant Tuberculosis, 2016 update. Eur Respir J. 2017;49(3). https:\/\/doi.org\/10.1183\/13993003.02308-2016.","DOI":"10.1183\/13993003.02308-2016"},{"issue":"4","key":"655_CR13","first-page":"411","volume":"30","author":"C Cavusoglu","year":"2007","unstructured":"Cavusoglu C, Soyler I, Akinci P. Activities of Linezolid against nontuberculous mycobacteria. New Microbiol. 2007;30(4):411\u20134.","journal-title":"New Microbiol"},{"issue":"3","key":"655_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/AAC.45.3.764-767.2001","volume":"45","author":"RJ Wallace","year":"2001","unstructured":"Wallace RJ, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001;45(3):764\u20137. https:\/\/doi.org\/10.1128\/AAC.45.3.764-767.2001.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"655_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1128\/JCM.02260-12","volume":"51","author":"A Broda","year":"2013","unstructured":"Broda A, Jebbari H, Beaton K, Mitchell S, Drobniewski F. Comparative drug resistance of Mycobacterium abscessus and M. Chelonae isolates from patients with and without cystic fibrosis in the United Kingdom. J Clin Microbiol. 2013;51(1):217\u201323. https:\/\/doi.org\/10.1128\/JCM.02260-12.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"655_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12879-017-2298-8","volume":"17","author":"S Hatakeyama","year":"2017","unstructured":"Hatakeyama S, Ohama Y, Okazaki M, Nukui Y, Moriya K. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan. BMC Infect Dis. 2017;17(1):197. https:\/\/doi.org\/10.1186\/s12879-017-2298-8.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"655_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.diagmicrobio.2017.09.013","volume":"90","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Lu J, Song Y, Pang Y. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagn Microbiol Infect Dis. 2018;90(1):31\u20134. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.09.013.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"655_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial Diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416. https:\/\/doi.org\/10.1164\/rccm.200604-571ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"655_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1183\/13993003.00535-2020","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: an Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020;71(4):905\u201313. https:\/\/doi.org\/10.1183\/13993003.00535-2020.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"655_CR20","doi-asserted-by":"publisher","first-page":"00170","DOI":"10.1183\/13993003","volume":"51","author":"J van Ingen","year":"2018","unstructured":"van Ingen J, Aksamit T, Andrejak C, B\u00f6ttger EC, Cambau E, Daley CL, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary Disease: an NTM-NET consensus statement. Eur Respir J. 2018;51(3):00170\u20132018. https:\/\/doi.org\/10.1183\/13993003.","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"655_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jfma.2020.05.028","volume":"119","author":"YW Weng","year":"2020","unstructured":"Weng YW, Huang CK, Sy CL, Wu KS, Tsai HC, Lee SS. Treatment for Mycobacterium abscessus complex-lung Disease. J Formos Med Assoc. 2020;119(Suppl 1):58\u2013S66. https:\/\/doi.org\/10.1016\/j.jfma.2020.05.028.","journal-title":"J Formos Med Assoc"},{"key":"655_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijid.2014.02.014","volume":"25","author":"WJ Nie","year":"2014","unstructured":"Nie WJ, Duan HF, Huang HR, Lu Y, Bi DP, Chu NH. Species identification of Mycobacterium abscessus subsp. Abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics. Int J Infect Dis. 2014;25:170\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2014.02.014.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"655_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","volume":"183","author":"WJ Koh","year":"2011","unstructured":"Koh WJ, Jeon K, Lee NY, Kim B-J, Kook Y-H, Lee S-H, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011;183(3):405\u201310. https:\/\/doi.org\/10.1164\/rccm.201003-0395OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ijid.2020.06.007","volume":"97","author":"M Shirata","year":"2020","unstructured":"Shirata M, Yoshimoto Y, Marumo S, Tamai K, Fukui M. In vitro efficacy of combinations of eight antimicrobial agents against Mycobacteroides Abscessus complex. Int J Infect Dis. 2020;97:270\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2020.06.007.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"655_CR25","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/jac\/dkg262","volume":"51","author":"D Honeybourne","year":"2003","unstructured":"Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003;51(6):1431\u20134. https:\/\/doi.org\/10.1093\/jac\/dkg262.","journal-title":"J Antimicrob Chemother"},{"key":"655_CR26","doi-asserted-by":"publisher","unstructured":"Ye M, Xu L, Zou Y, Li B, Guo Q, Zhang Y, et al. Molecular Analysis of Linezolid-Resistant Clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(2). https:\/\/doi.org\/10.1128\/AAC.01842-18.","DOI":"10.1128\/AAC.01842-18"},{"issue":"2","key":"655_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/AAC.05702-11","volume":"56","author":"KS Long","year":"2012","unstructured":"Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother. 2012;56(2):603\u201312. https:\/\/doi.org\/10.1128\/AAC.05702-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"655_CR28","doi-asserted-by":"publisher","unstructured":"Zong Z, Jing W, Shi J, Wen S, Zhang T, Huo F, et al. Comparison of in Vitro Activity and MIC distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China. Antimicrob Agents Chemother. 2018;62(8). https:\/\/doi.org\/10.1128\/AAC.00165-18.","DOI":"10.1128\/AAC.00165-18"},{"key":"655_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12866-014-0292-5","volume":"14","author":"Y Tian","year":"2014","unstructured":"Tian Y, Li T, Zhu Y, Wang B, Zou X, Li M. Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China. BMC Microbiol. 2014;14:292. https:\/\/doi.org\/10.1186\/s12866-014-0292-5.","journal-title":"BMC Microbiol"},{"key":"655_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rmcr.2017.11.007","volume":"23","author":"T Inoue","year":"2018","unstructured":"Inoue T, Tsunoda A, Nishimoto E, Nishida K, Komatsubara Y, Onoe R, et al. Successful use of linezolid for refractory Mycobacterium abcessus Infection: a case report. Respir Med Case Rep. 2018;23:43\u20135. https:\/\/doi.org\/10.1016\/j.rmcr.2017.11.007.","journal-title":"Respir Med Case Rep"},{"key":"655_CR31","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3389\/fmicb.2019.01977","volume":"10","author":"JH Chen","year":"2019","unstructured":"Chen JH, Zhao L, Mao YH, Ye MP, Guo Q, Zhang YJ, et al. Clinical efficacy and adverse effects of Antibiotics used to treat Mycobacterium abscessus Pulmonary Disease. Front Microbiol. 2019;10:1977. https:\/\/doi.org\/10.3389\/fmicb.2019.01977.","journal-title":"Front Microbiol"},{"key":"655_CR32","doi-asserted-by":"publisher","unstructured":"Li H, Tong L, Wang J, Liang Q, Zhang Y, Chu N et al. An Intensified Regimen Containing Linezolid Could Improve Treatment Response in Mycobacterium abscessus Lung Disease. Biomed Res Int 2019; 2019: 8631563. https:\/\/doi.org\/10.1155\/2019\/8631563.","DOI":"10.1155\/2019\/8631563"},{"issue":"7","key":"655_CR33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/01.ccm.0000168206.59873.80","volume":"33","author":"E Boselli","year":"2005","unstructured":"Boselli E, Breilh D, Rimmel\u00e9 T, Djabarouti S, Toutain J, Chassard D, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated Pneumonia. Crit Care Med. 2005;33(7):1529\u201333. https:\/\/doi.org\/10.1097\/01.ccm.0000168206.59873.80.","journal-title":"Crit Care Med"},{"issue":"5","key":"655_CR34","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","volume":"46","author":"JE Conte Jr","year":"2002","unstructured":"Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46(5):1475\u201380. https:\/\/doi.org\/10.1128\/AAC.46.5.1475-1480.2002.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"655_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","volume":"45","author":"S Tang","year":"2015","unstructured":"Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161\u201370. https:\/\/doi.org\/10.1183\/09031936.00035114.","journal-title":"Eur Respir J"},{"issue":"2","key":"655_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jac\/dkp171","volume":"64","author":"WJ Koh","year":"2009","unstructured":"Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, et al. Daily 300\u00a0mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant Tuberculosis. J Antimicrob Chemother. 2009;64(2):388\u201391. https:\/\/doi.org\/10.1093\/jac\/dkp171.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"655_CR37","doi-asserted-by":"publisher","first-page":"ofab093","DOI":"10.1093\/ofid\/ofab093","volume":"8","author":"YK Poon","year":"2021","unstructured":"Poon YK, La Hoz RM, Hynan LS, Sanders J, Monogue ML. Tedizolid vs Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant recipients. Open Forum Infect Dis. 2021;8(4):ofab093. https:\/\/doi.org\/10.1093\/ofid\/ofab093.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"655_CR38","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1183\/09031936.00169114","volume":"45","author":"KL Winthrop","year":"2015","unstructured":"Winthrop KL, Ku JH, Marras TK, Griffith DE, Daley CL, Olivier KN, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial Disease. Eur Respir J. 2015;45(4):1177\u20139. https:\/\/doi.org\/10.1183\/09031936.00169114.","journal-title":"Eur Respir J"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-023-00655-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-023-00655-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-023-00655-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T11:02:54Z","timestamp":1701860574000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-023-00655-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1186\/s12941-023-00655-2","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committees of Shanghai Pulmonary Hospital (Ethics No. fk22-005). Verbal informed consent to use medical records for this retrospective study was obtained from all subjects involved in this study. All information for analysis is managed under the supervision of the Ethical Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}